Trial ID or NCT#



recruiting iconRECRUITING


This is a randomized, multi-center, prospective, double blind study. The primary objective is to demonstrate the efficacy of RP-1127 compared to placebo in subjects with a severe anterior circulation ischemic stroke who are likely to develop malignant edema. This objective will be addressed by comparing the proportion of RP-1127 treated patients and placebo treated patients with a Day 90 modified Rankin Scale (mRS) ≤ 4 without decompressive craniectomy (DC).

Official Title

A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema

Eligibility Criteria

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Gregory W. Albers, MD
Gregory W. Albers, MD
Stroke and vascular neurologist
The Coyote Foundation Professor and Professor, by courtesy, of Neurosurgery at the Stanford University Medical Center

Contact us to find out if this trial is right for you.


Stephanie Kemp